StocksFundsScreenerSectorsWatchlists
FIXX

FIXX - Homology Medicines Inc Stock Price, Fair Value and News

16.55USD+15.62 (+1679.57%)Delayed as of 28 Mar 2024, 09:48 am ET

Market Summary

FIXX
USD16.55+15.62
Delayedas of 28 Mar 2024, 09:48 am
1679.57%

FIXX Stock Price

View Fullscreen

FIXX RSI Chart

FIXX Valuation

Market Cap

54.0M

Price/Earnings (Trailing)

-0.48

Price/Sales (Trailing)

16.62

EV/EBITDA

-0.17

Price/Free Cashflow

-0.56

FIXX Price/Sales (Trailing)

FIXX Profitability

EBT Margin

-2682.69%

Return on Equity

-154.76%

Return on Assets

-133.58%

Free Cashflow Yield

-178.77%

FIXX Fundamentals

FIXX Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

FIXX Earnings

Earnings (TTM)

-113.0M

Earnings Growth (Yr)

53%

Earnings Growth (Qtr)

51.09%

Breaking Down FIXX Revenue

52 Week Range

0.8016.55
(Low)(High)

Last 7 days

1715.2%

Last 30 days

1987.5%

Last 90 days

2829.8%

Trailing 12 Months

1657.9%

How does FIXX drawdown profile look like?

FIXX Financial Health

Current Ratio

7.25

FIXX Investor Care

Shares Dilution (1Y)

0.93%

Diluted EPS (TTM)

-1.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.9M3.4M4.0M3.2M
202226.3M18.6M10.9M3.2M
202131.4M33.0M34.1M34.0M
20201.9M2.2M2.4M2.7M
20194.5M4.8M4.9M1.7M
2018004.3M4.3M
20170000

Tracking the Latest Insider Buys and Sells of Homology Medicines Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 25, 2024
alloway paul
acquired
-
-
23,530
see remarks
Mar 25, 2024
michaud charles jr
acquired
-
-
6,448
see remarks
Jan 09, 2024
tzianabos arthur
sold
-7,445
0.5711
-13,037
-
Jan 03, 2024
alloway paul
sold
-4,120
0.566
-7,280
see remarks
Jan 03, 2024
michaud charles jr
sold
-975
0.571
-1,708
see remarks
Jan 01, 2024
michaud charles jr
acquired
-
-
4,240
see remarks
Jan 01, 2024
tzianabos arthur
acquired
-
-
33,420
-
Jan 01, 2024
alloway paul
acquired
-
-
18,610
see remarks
Sep 06, 2023
seymour albert
acquired
-
-
4,620
see remarks
Sep 06, 2023
seymour albert
sold
-1,665
1.1502
-1,448
see remarks

1–10 of 50

Which funds bought or sold FIXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
reduced
-5.22
-1,215,070
1,179,270
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
95.14
420
30,222
-%
Feb 27, 2024
Beaird Harris Wealth Management, LLC
sold off
-100
-191
-
-%
Feb 26, 2024
Virtu Financial LLC
new
-
21,000
21,000
-%
Feb 15, 2024
BARCLAYS PLC
unchanged
-
-30,000
33,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
14,379
14,379
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-11,775
-
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-14.13
-74,764
60,241
-%
Feb 14, 2024
Western Standard LLC
sold off
-100
-292,570
-
-%
Feb 14, 2024
Newtyn Management, LLC
new
-
850,750
850,750
0.17%

1–10 of 46

Are Funds Buying or Selling FIXX?

Are funds buying FIXX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FIXX
No. of Funds

Unveiling Homology Medicines Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 08, 2022
blackrock inc.
2.9%
1,656,676
SC 13G
Feb 14, 2022
temasek holdings (private) ltd
9.9%
5,650,996
SC 13G/A
Feb 03, 2022
blackrock inc.
6.3%
3,587,777
SC 13G/A
May 06, 2021
jpmorgan chase & co
2.0%
1,185,457
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
4.3%
1,986,298
SC 13G/A
Feb 16, 2021
5am ventures iv, l.p.
9.6%
4,354,484
SC 13G/A
Feb 12, 2021
rtw investments, lp
0%
0
SC 13G/A
Feb 02, 2021
blackrock inc.
6.1%
2,763,142
SC 13G
Jan 25, 2021
jpmorgan chase & co
7.6%
3,441,712
SC 13G/A
Nov 19, 2020
pfizer inc
9.9%
0
SC 13G

Recent SEC filings of Homology Medicines Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
3
Insider Trading
Mar 27, 2024
8-K
Current Report
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading

Peers (Alternatives to Homology Medicines Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Homology Medicines Inc News

Latest updates
Marketscreener.com • 34 hours ago
Investing.com • 20 Mar 2024 • 09:35 pm
InvestorPlace • 16 Mar 2024 • 01:53 am
InvestorsObserver • 05 Feb 2024 • 08:00 am
Seeking Alpha • 4 months ago

Homology Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-100.0%-1,423,000354,0001,469,000802,000802,000802,000802,000802,0001,677,0002,187,00029,305,000980,000567,000567,000588,0001,124,5001,661,0001,703,0001,271,000223,000
Operating Expenses-61.0%12,101,00031,001,00031,170,00028,313,00035,296,00033,664,00029,109,00038,420,00034,427,00032,338,00032,739,00030,416,00030,781,50028,840,00036,264,00037,080,00026,122,00031,729,00028,365,00025,393,00021,368,500
  S&GA Expenses15.5%7,901,0006,842,0008,188,0008,325,0008,147,0007,810,0008,034,00014,147,00010,781,0008,351,0009,042,0008,661,0007,587,0008,423,0008,793,0007,770,0005,779,0006,038,0005,538,0004,857,0005,094,500
  R&D Expenses-91.4%1,513,00017,519,00022,982,00019,988,00027,149,00025,854,00021,075,00024,273,00023,646,00023,987,00023,697,00021,755,00023,194,50020,417,00027,471,00029,310,00020,343,00025,691,00022,827,00020,536,00016,274,000
EBITDA Margin7.8%-26.66-28.93-34.71-30.290.760.340.350.21-2.57------------
Income Taxes------212,000-46,000100,0001,000,000-------------
Earnings Before Taxes92.7%-2,155,000-29,578,000-29,305,000-26,042,000-33,039,000-31,593,000-27,833,00093,663,000-33,583,000-30,608,000-30,500,000-1,073,000---------
EBT Margin7.9%-26.83-29.14-35.01-30.580.370.060.09-0.04-2.82------------
Net Income51.1%-16,119,000-32,954,000-35,044,000-28,844,000-34,295,000-33,726,000-29,089,00092,105,000-33,583,000-30,608,000-30,500,000-1,073,000-29,791,000-28,232,000-35,340,000-35,331,000-24,167,000-29,627,000-26,270,000-23,852,000-18,786,000
Net Income Margin-7.4%-34.80-32.40-38.49-32.50-1.56-0.39-0.06-0.10-2.82-2.69-2.71-3.01---------
Free Cashflow13.5%-21,575,000-24,941,000-23,660,000-26,282,000-27,208,000-24,938,000-30,967,000-31,833,000-30,768,000-25,864,000-24,875,000-30,640,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-39.6%85.00140169198228263285311212231259235264228258289311317341233259
  Current Assets-21.3%84.00107131154181213238262192192218192220181210238267274299191222
    Cash Equivalents34.9%39.0029.0077.0039.0034.0043.0017624810896.0011610421717816814354.0078.0011641.0038.00
  Net PPE---1.001.001.001.002.002.002.0033.0034.0036.0037.0040.0041.0043.0043.0041.0041.0041.0036.00
Liabilities-77.7%12.0052.0050.0046.0050.0054.0044.0045.0042.0032.0034.0034.0068.0058.0064.0062.0052.0059.0056.0059.0063.00
  Current Liabilities-54.2%12.0025.0023.0019.0023.0025.0021.0021.0017.0019.0020.0018.0023.0017.0020.0017.0012.0019.0015.0018.0023.00
Shareholder's Equity-17.3%73.0088.00119152178209240266170199225201196170195227259258285174196
  Retained Earnings-3.1%-542-525-493-458-429-394-361-332-424-390-359-329-328-298-270-235-199-175-145-119-95.76
  Additional Paid-In Capital-100.0%-614612610608604601598594589585530524469465462458433430294292
Shares Outstanding0.2%58.0058.0058.0058.0057.0057.0057.0057.0057.0055.0053.0050.00---------
Float-------92.00---339---512---514--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations13.5%-21,575-24,941-23,660-26,054-27,199-24,932-30,846-30,684-30,430-25,387-24,111-29,823-11,612-28,887-27,987-25,846-26,333-25,484-21,670-17,871-8,079
  Share Based Compensation-50.4%8471,7062,4022,3693,0892,7713,1434,0514,6634,2264,4733,8833,5663,3463,4532,8832,4361,9861,9701,243955
Cashflow From Investing239.3%31,716-22,76361,00131,37217,991-108,218-41,369168,31243,6614,524-13,738-85,235-95538,84452,010114,997-20,027-13,137-38,30219,66710,202
Cashflow From Financing-22.2%14.0018.002.0015032.00124-4401.0037949,7462,04351,99541024144722,575614134,69932541.00

FIXX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]  
Collaboration revenue$ 1,156$ 3,208
Operating expenses:  
Research and development62,00298,351
General and administrative31,25638,138
Restructuring and Other Charges9,3270
Total operating expenses102,585136,489
Loss from operations(101,429)(133,281)
Other income:  
Gain on sale of business0131,249
Gain on lease termination8,7670
Interest income5,5823,230
Total other income14,349134,479
Income (loss) before income taxes(87,080)1,198
Provision for income taxes0(715)
Loss from equity method investment(25,881)(5,488)
Net loss$ (112,961)$ (5,005)
Net loss per share-basic$ (1.95)$ (0.09)
Net loss per share-diluted$ (1.95)$ (0.09)
Weighted average common shares outstanding-basic57,834,81957,399,762
Weighted average common shares outstanding-diluted57,834,81957,399,762

FIXX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 39,266$ 33,986
Short-term investments43,387141,040
Assets Held For Sale2600
Prepaid expenses and other current assets1,0015,989
Total current assets83,914181,015
Equity method investment025,814
Property and equipment, net01,078
Right-of-use assets65020,563
Total assets84,564228,470
Current liabilities:  
Accounts payable3,2341,144
Accrued expenses and other liabilities7,02118,715
Operating Lease Liabilities1,3181,561
Deferred revenue01,156
Total current liabilities11,57322,576
Non-current liabilities:  
Operating lease liabilities, net of current portion027,916
Total liabilities11,57350,492
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 202200
Common stock, $0.0001 par value; 200,000,000 shares authorized; 58,017,412 and 57,483,910 shares issued and outstanding as of December 31, 2023 and 2022, respectively66
Additional paid-in capital615,088607,513
Accumulated other comprehensive gain(5)(404)
Accumulated deficit(542,098)(429,137)
Total stockholders’ equity72,991177,978
Total liabilities and stockholders' equity$ 84,564$ 228,470
FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEwww.homologymedicines.com
 EMPLOYEES92

Homology Medicines Inc Frequently Asked Questions


What is the ticker symbol for Homology Medicines Inc? What does FIXX stand for in stocks?

FIXX is the stock ticker symbol of Homology Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Homology Medicines Inc (FIXX)?

As of Mon Mar 25 2024, market cap of Homology Medicines Inc is 53.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FIXX stock?

You can check FIXX's fair value in chart for subscribers.

What is the fair value of FIXX stock?

You can check FIXX's fair value in chart for subscribers. The fair value of Homology Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Homology Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FIXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Homology Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether FIXX is over valued or under valued. Whether Homology Medicines Inc is cheap or expensive depends on the assumptions which impact Homology Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FIXX.

What is Homology Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Mar 25 2024, FIXX's PE ratio (Price to Earnings) is -0.48 and Price to Sales (PS) ratio is 16.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FIXX PE ratio will change depending on the future growth rate expectations of investors.